Topical Estrogen Formulations for Dry Eye Sustained Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dry eye syndrome, such as keratoconjunctivitis sicca, often require frequent dosing of 17-β-estradiol and can cause systemic side effects, with existing formulations not providing a sustained release profile or effective micro-dose delivery.
Innovation Solution
Development of topical pharmaceutical compositions with 17-β-estradiol or its analogs in timed-release formulations, using bioadhesive viscoelastic compounds like polycarbophil, hyaluronate, and liposomes, for delivery to the ocular surface, allowing for reduced dosing frequency while maintaining therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If frequent dosing of 17-β-estradiol is used to treat dry eye syndrome, then therapeutic efficacy is maintained, but patient compliance deteriorates and dosing frequency increases
Solution Approach 1:
The patent applies preliminary action by incorporating 17-β-estradiol into bioadhesive viscoelastic compounds and lipid formulations before administration. These formulations are designed to adhere to the ocular surface and release the hormone gradually over time, eliminating the need for frequent dosing while maintaining therapeutic efficacy. The preliminary formulation preparation enables sustained release without requiring frequent patient intervention.
Solution Approach 2:
The patent uses bioadhesive viscoelastic compounds and lipid structures as intermediaries to deliver 17-β-estradiol to the ocular surface. These intermediaries adhere to the eye surface and control the release rate of the hormone, acting as a mediator between the administered dose and the target tissue. This intermediary system enables sustained therapeutic levels without frequent re-dosing.
2Reliability
If oral or parenteral administration of estrogen is used to treat dry eye syndrome, then systemic hormone levels are achieved, but systemic side effects increase and localized delivery efficiency decreases
Solution Approach 1:
The patent applies local quality by formulating 17-β-estradiol in bioadhesive viscoelastic compounds specifically designed for ocular surface adherence. The formulation concentrates the hormone at the site of action (ocular surface and tear fluid) rather than distributing it systemically. This localized delivery achieves therapeutic efficacy in the target tissue while avoiding systemic side effects associated with oral or parenteral administration.
Solution Approach 2:
The patent extracts the hormone delivery from the systemic circulation pathway and redirects it to the ocular surface through topical application. By removing the need for oral or parenteral administration, the formulation extracts the harmful systemic distribution effect while retaining the beneficial localized therapeutic effect on the tear film and ocular surface.
3Reliability
If high concentration of 17-β-estradiol is used in topical formulations, then therapeutic effect is enhanced, but risk of systemic absorption and side effects increases
Solution Approach 1:
The patent uses bioadhesive viscoelastic compounds as intermediaries that control the release rate of 17-β-estradiol from the formulation. This intermediary system maintains high local concentration at the ocular surface for therapeutic effect while controlling the rate of entry into systemic circulation, thereby reducing systemic absorption risk even when using effective concentrations of the hormone.
Solution Approach 2:
The patent employs lipid formulations and bioadhesive films that create a reservoir on the ocular surface, releasing the hormone gradually. This film-based approach maintains high local concentration where needed while the controlled release mechanism prevents excessive systemic absorption, balancing therapeutic effect with safety.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The timed-release formulations provide a sustained drug release rate, reducing systemic side effects and allowing for effective treatment of dry eye syndrome with lower doses, administered less frequently, thereby improving patient compliance and treatment efficacy.
Implementation Method 1
topical pharmaceutical compositions with 17-β-estradiol or its analogs in timed-release formulations, using bioadhesive viscoelastic compounds like polycarbophil, hyaluronate, and liposomes, for delivery to the ocular surface
Implementation Method 2
The timed-release formulations provide a sustained drug release rate
Data Source
AI summary
A topical application formulation of estrogen and estrogen analogs or other estrogen receptor modulators is disclosed for the treatment of primary or secondary dry eye syndrome (also known as keratoconjunctivitis sicca (KCS)). Preferred formulations include 17-β-estradiol and its derivatives in lipid, liposomes, polymers, or aqueous or non-aqueous vehicles for the topical treatment of the ocular surface tissues particularly as time-release or micro-dose formulations. These formulations may also be useful in treating other conditions where KCS may occur, such as post-operative refractive surgery and corneal transplant patients.